Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia

Diagnostic Microbiology and Infectious Disease

Volumn 44, Issue 1, 2002, Pages 117-125

  Nicholson, Susan C ^a,b   Wilson, Walter R ^c   Naughton, Bruce J ^d   Gothelf, Samantha ^a   Webb, C Douglas ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

Community acquired pneumonia; Elderly; Gatifloxacin

Indexed keywords

ANTIINFECTIVE AGENT; GATIFLOXACIN;

AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEVER; GRAM STAINING; HAEMOPHILUS INFLUENZAE; HALLUCINATION; HEADACHE; HISTORY OF MEDICINE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATHOGENESIS; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; RASH; STREPTOCOCCUS PNEUMONIAE; THORAX PAIN;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; MALE; OUTPATIENTS; PNEUMONIA, BACTERIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0036746008     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00465-0     Document Type: Article

References (33)

1. Baik I., Curhan G.C., Rimm E.B., Bendich A., Willett W., Fawzi W.W. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch Intern Med. 160:2000;3082-3088.
2. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M. Jr., Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 31:2000;347-382.
3. Brown P.D., Lerner S.A. Community-acquired pneumonia. Lancet. 352:1998;1295-1302.
4. Centers for Disease Control. Influenza and pneumococcal vaccination levels among adults aged greater than or equal to 65 years - United States. MMWR. 47:1998;797-802.
5. COSTART - Coding symbols for thesaurus of adverse reaction terms. 5th ed: 1995;Food and Drug Administration, Rockville, MD.
6. Farr B.M., Woodhead M.A., Macfarlane J.T., Bartlett C.L.R., McCracken J.S., Wadsworth J., Miller D.L. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med. 94:2000;422-427.
7. Fein A.M. Pneumonia in the elderly Overview of diagnostic and therapeutic approaches . Clin Infect Dis. 28:1999;726-729.
8. Feldman C. Pneumonia in the elderly. Clin Chest Med. 20:1999;563-573.
9. Fine M.J., Auble T.E., Yealy D.M., Hanusa B.H., Weissfeld L.A., Singer D.E., Coley C.M., Marrie T.J., Kapoor W.N. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 336:1997;243-250.
10. Gajjar D.A., LaCreta F.P., Uderman H.D., Kollia G.D., Duncan G., Birkhofer M.J., Grasela D.M. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy. 20:2000;49S-58S.
11. Gajjar D.A., LaCreta F.P., Kollia G.D., Stolz R.R., Berger S., Smith W.B., Swingle M., Grasela D.M. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy. 20:2000;76S-86S.
12. Gleason P.P., Meehan T.P., Fine J.M., Galusha D.H., Fine M.J. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 159:1999;2562-2572.
13. Gotfried M., Freeman C. An update on community-acquired pneumonia in adults. Comp Ther. 26:2000;283-293.
14. Gotfried M., Quinn T., Gothelf S., Wikler M.A., Webb C.D., Nicholson S.C. Oral gatifloxacin in outpatient community-acquired pneumonia Results from TeqCES, a community-based, open-label, multicenter study . Diagn Microbiol Infect Dis. 2000;. [complete citation to come].
15. Grasela, D. M., LaCreta, F. P., Kollia, G. D., Rnadall, D. M., Stoltz, R. R., & Berger, S. (1999). Lack of effect of multiple-dose gatifloxacin on oral glucose tolerance, glucose and insulin homeostasis, and glyburide pharmacokinetics in type II, non-insulin-dependent diabetes mellitus (NIDDM). Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy: San Francisco, September 26-29, 1999.
16. Heffelfinger J.D., Dowell S.F., Jorgensen J.H., Klugman K.P., Mabry L.R., Musher D.M., Plouffe J.F., Rakowsky A., Schuchat A., Whitney C.G., the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group . Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med. 160:2000;1399-1408.
17. Mandell L.A., Marrie T.J., Grossman R.F., Chow A.W., Hyland R.H., the Canadian Community-Acquired Pneumonia Working Group . Canadian guidelines for the initial management of community-acquired pneumonia An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society . Clin Infect Dis. 31:2000;383-421.
18. Moroney C., Fitzgerald M.A. Pharmacologic update. Management of pneumonia in elderly people. J Am Acad Nurse Pract. 8:1996;237-241.
19. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, tenth informational supplement M100-S10. 2000a;NCCLS, Wayne, PA.
20. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard M7-A5. 5th ed: 2000b;NCCLS, Wayne, PA.
21. Nguyen-Van-Tam J.S., Neal K.R. Clinical effectiveness, policies, and practices for influenza and pneumococcal vaccines. Semin Respir Infec. 14:1999;184-195.
22. Nicolle L.E. Quinolones in the aged. Drugs. 58:(Suppl 2):1999;49-51.
23. Nicholson S.C., High K.H., Gothelf S., Webb C.D. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. Diagn Microbiol Infect Dis. 2002;. [complete citation to come].
24. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., Dean N., File T., Fine M.J., Gross P.A., Martinez F., Marrie T.J., Plouffe J.F., Ramirez J., Sarosi G.A., Torres A., Wilson R., Yu V.L. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 163:2001;1730-1754.
25. Nuorti J.P., Butler J.C., Crutcher J.M., Guevara J.M., Welch D., Holder P., Elliott J.A. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med. 338:1998;1861-1868.
26. Ortqvist A. Pneumoccal vaccination Current and future issues . Eur Respir J. 18:2001;184-195.
27. Peterson P.K., Stein D., Guay D.R., Logan G., Obaid S., Gruninger R., Davies S., Breitenbucher R. Prospective study of lower respiratory tract infections in an extended-care nursing home program Potential role of oral ciprofloxacin . Am J Med. 85:1988;164-171.
28. Pfaller M.A., Ehrhardt A.F., Jones R.N. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the Respiratory Surveillance Program Study Microbiology from the medical office practice environment . Am J Med. 111:(Suppl 1):2001;4-12.
29. Ramirez J.A., Nguyen T.-H., Tellier G., Coppola G., Bettis R.B., Dolmann A., St-Pierre C., Mayer H. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin. J Respir Dis. 20:(11 Suppl):1999;S40-S48.
30. Rubins J.B., Alter M., Loch J., Janoff E.N. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun. 67:1999;5979-5984.
31. Stalam M., Kaye D. Antibiotic agents in the elderly. Infect Dis Clin North Am. 14:2000;357-369.
32. Sullivan J.G., McElroy A.D., Honsinger R.W., McAdoo M., Harrison B.J., Plouffe J.F., Gotfried M., Mayer H. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. J Respir Dis. 20:(11 Suppl):1999;S49-S59.
33. Von Seggern, K., Russo, R., Wikler, M. A. (2000). A novel approach to postmarketing surveillance: The Tequin clinical experience study. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington D.C.: American Society for Microbiology, 468. Abstract 2216.